secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0000950170-21-001181
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside reports Q2 2021 net loss $6.1M; OASIS Cohort 2 underway; XIPERE PDUFA Oct 30
--------------------------------------------------------------------------------

- Net loss of $6.1M ($0.11/share) vs $5.8M ($0.13/share) in Q2 2020.
- Revenue of $0.8M from partner licensing; cash $26.4M to fund ops into Q2 2022.
- OASIS Phase 1/2a wet AMD: Cohort 1 met safety endpoints; Cohort 2 enrollment (0.1 mg dose) underway.
- XIPERE NDA resubmission accepted; FDA PDUFA action date of October 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017021001181/0000950170-21-001181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017021001181/clsd-20210810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer